Given that inhibition of the TRPM2 channel and Zn2+ chelation rescues the structural and functional integrity of mitochondria in various oxidative stress-linked disease models, including cardiovascular and metabolic diseases, we believe that this mechanism offers new opportunities for a ‘common’ mitochondrial medicine for a wide range of diseases, with potential for prophylactic use. Here, TRPM2 is linked to metabolic disease.